Abstract
Background The clinical case definition for measles is highly sensitive and has low specificity. Diag-nostic confirmation can resolve this uncertainty for individual cases and is a crucial tool for confirmation of measles outbreaks. However, in under-resourced settings, it is prohibitive to confirm all suspected cases and routine measles surveillance comprises a combination of both clinically and diagnostically confirmed cases.
Methods We developed a dynamic model of measles, rubella, and other sources of febrile rash to simulate time series of a suspected measles surveillance system. We simulated partial reporting of suspected cases and limited routine diagnostic testing using assays with sensitivity and specificity that correspond to current or proposed rapid diagnostic tests. We estimated the time series of reported measles cases as the product of suspected cases and the proportion of diagnostic positive cases. We then estimated the reporting rate and annual incidence for measles using the time-series SIR model.
Results Reconstructing the time series of reported measles cases using the fraction of diagnostic positive cases results in unbiased estimates of the reporting rate and the annual incidence at moderate vaccination levels for all reasonable levels of test sensitivity and specificity, even for low proportions tested. At high vaccination levels, diagnostic tests with low sensitivity (< 90%) lead to slight bias in annual incidence. Temporal variation in the prevalence of measles among suspected cases require that the proportion of cases attributable to measles be estimated frequently (i.e., monthly) to avoid bias in estimates.
Conclusion Combining routine, systematic diagnostic confirmation of suspected measles cases with suspected cases surveillance can improve estimates of the reporting rate and annual incidence using diagnostic tests with sensitivity and specificity consistent with proposed rapid diagnostic tests.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Gavi, the Vaccine Alliance.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
